Palatin Technologies (PTN) Accounts Payables (2011 - 2026)
Palatin Technologies' (PTN) quarterly Accounts Payables came in at $1.7 million in Q1 2026, down 78.21% YoY from $7.8 million in Q1 2025, and down 68.95% on a QoQ basis from $5.5 million in Q4 2025.
Palatin Technologies (PTN) Accounts Payables (2011 - 2026) Analysis & Trends
Palatin Technologies (PTN) has 15 years of Accounts Payables data on file, last reported at $1.7 million in Q1 2026.
- Quarterly Accounts Payables fell 78.21% year-over-year to $1.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.7 million (down 78.21% YoY) and the FY2025 annual result came in at $7.0 million, up 70.62% from the prior year.
- Accounts Payables slipped to $1.7 million in Q1 2026, from $5.5 million in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $7.8 million in Q1 2025 to a low of $820304.0 in Q4 2022.
- A 5-year average of $4.0 million and a median of $3.8 million in 2022 frame the typical range for Accounts Payables.
- Annual changes were most pronounced in 2022 — Accounts Payables soared 412.11% — and 2026, when it sank 78.21%.
- Tracing PTN's Accounts Payables over 5 years: stood at $820304.0 in 2022, then surged by 94.25% to $1.6 million in 2023, then surged by 321.61% to $6.7 million in 2024, then dropped by 18.83% to $5.5 million in 2025, then plunged by 68.95% to $1.7 million in 2026.
- The last three Accounts Payables figures came in at $1.7 million (Q1 2026), $5.5 million (Q4 2025), and $7.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Palatin Technologies | 40.37 Mn | 40.37 Mn | - | 1.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.69 Mn |
| Dec 31, 2025 | 5.45 Mn |
| Sep 30, 2025 | 7.41 Mn |
| Jun 30, 2025 | 7.00 Mn |
| Mar 31, 2025 | 7.77 Mn |
| Dec 31, 2024 | 6.72 Mn |
| Sep 30, 2024 | 3.95 Mn |
| Jun 30, 2024 | 4.10 Mn |
| Mar 31, 2024 | 3.44 Mn |
| Dec 31, 2023 | 1.59 Mn |
| Sep 30, 2023 | 2.27 Mn |
| Jun 30, 2023 | 4.30 Mn |
| Mar 31, 2023 | 2.79 Mn |
| Dec 31, 2022 | 820,304.00 |
| Sep 30, 2022 | 3.77 Mn |
| Jun 30, 2022 | 3.16 Mn |
| Mar 31, 2022 | 2.40 Mn |
| Dec 31, 2021 | 160,180.00 |
| Sep 30, 2021 | 762,817.00 |
| Jun 30, 2021 | 640,650.00 |